Related Experiment Video
Updated: Jun 7, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Aspirin for the prevention of cardiovascular morbidity
M Sanchez-Ross1, A H Waller, J Maher
1University Hospital, UMDNJ, Newark, USA.
Insights
Aspirin (acetylsalicylic acid) use for cardiovascular event prevention shows benefits but emerging data questions its widespread primary prevention recommendations. Physicians must balance aspirin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Aspirin (acetylsalicylic acid, ASA) is established for secondary cardiovascular (CV) event prevention.
- Current guidelines recommend ASA for primary CV event prevention in moderate-high risk adults.
- Emerging data challenges the efficacy and safety of these recommendations.
Purpose of the Study:
- To review contemporary trial data on ASA efficacy and safety in various patient subsets.
- To propose strategies for enhancing ASA's safety and efficacy in primary prevention.
- To guide physicians in balancing CV risk reduction against bleeding risks.
Main Methods:
- Review of recent randomized clinical trials on aspirin use.
- Analysis of efficacy and safety data across different patient populations.
- Synthesis of strategies for optimizing aspirin therapy.
Main Results:
- Contemporary data presents a nuanced view on aspirin's benefits versus risks.
- Efficacy and safety profiles vary significantly among patient subsets.
- Bleeding complications remain a primary concern.
Conclusions:
- Re-evaluation of aspirin's role in primary CV event prevention is warranted.
- Personalized risk-benefit assessment is crucial before prescribing aspirin.
- Combined strategies may enhance aspirin's therapeutic index for primary prevention.
Abstract:
Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality. This beneficial effect of ASA seems to consistently outweigh the risk in most patient subsets. Current guidelines endorse ASA for primary prevention of CV events in adults who are at moderate-high risk of CV morbidity. Recent emerging data on the efficacy and safety of ASA conflicts with former randomized clinical trials and raises concerns regarding the validity of these recommendations. The following manuscript describes the data emerging from contemporary trials regarding the efficacy and safety of ASA in various patient subsets. The authors propose certain strategies to enhance safety and efficacy in order to augment the beneficial effects of ASA along with other modalities of primary prevention for suitable candidates. When contemplating ASA prescription for primary prevention of CV events, physicians should carefully weigh the potential benefits of risk reduction versus likelihood of harm, mostly related to bleeding complications.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Cardiovascular Drugs: Classification based on Therapeutic Indications
